PKM and lung cancer: Consistent with its role in glycolysis, PKM2 knockdown decreases glycolytic activity in both H1299 (derived from human lung cancer) and HepG2 (derived from human liver cancer) cells, as judged by measuring the extracellular acidification rate (ECAR) (Fig. 1A and 1B).